← Back
Data updated: Mar 10, 2026
CHATTEM SANOFI
MetabolicOncologyRespiratory
CHATTEM SANOFI is a major pharmaceutical company focused on Metabolic, Oncology, Respiratory. Key products include XYZAL ALLERGY 24HR.
1983
Since
15
Drugs
-
Trials
6
Approved (2yr)
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Metabolic 36%
0 drugs Phase 3: 34 Phase 2: 7 Phase 1: 50
Oncology 20%
0 drugs Phase 3: 8 Phase 2: 21 Phase 1: 34
Respiratory 16%
0 drugs Phase 3: 14 Phase 2: 11 Phase 1: 8
Cardiovascular 15%
0 drugs Phase 3: 19 Phase 2: 2 Phase 1: 4
Immunology 13%
0 drugs Phase 3: 7 Phase 2: 16 Phase 1: 10
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Oncology, Cardiovascular, Immunology, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic, Immunology
Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Immunology, Cardiovascular
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Active (7)
Discontinued (8)
Company Info
- First Approval
- 1983-12-09
- Latest
- 2025-07-22
- Applications
- 18